Summit Therapeutics shares moved higher Wednesday as the market leaned into a catalyst-driven setup tied to ivonescimab, the company’s lead PD-1/VEGF bispecific antibody. The company has outlined a planned interim progression-free survival (PFS) analysis in Q2 2026 for the squamous cohort of its global Phase III HARMONi-3 trial in first-line metastatic non-small cell lung cancer (NSCLC), which has become the most watched near-term data event for the stock. (smmttx.com)

In recent weeks, Summit also drew renewed investor attention after announcing multiple Phase III ivonescimab datasets would be presented at the 2026 European Lung Cancer Congress (ELCC 2026), including a poster focused on intracranial efficacy in EGFR-mutated NSCLC patients with and without baseline asymptomatic brain metastases. With the next data checkpoint approaching and sentiment highly reactive to incremental clinical updates, even modest flows can translate into outsized daily moves. (smmttx.com)

SMMT has shown conditions that can magnify price swings around catalysts, including heightened short-squeeze sensitivity cited by market commentary that points to elevated short interest and positioning ahead of the Q2 interim analysis. That dynamic can push incremental buying into sharper intraday gains as shorts reduce exposure into binary events. (tipranks.com)

The key question for the next leg is whether the HARMONi-3 interim PFS analysis in the squamous cohort delivers a clear efficacy signal that supports ivonescimab’s competitiveness in first-line NSCLC. Beyond that, investors are tracking the broader late-stage timeline for HARMONi-3 (including final analyses) and how quickly Summit can translate global trial execution into an eventual U.S. regulatory filing package for ivonescimab. (marketbeat.com)